Duloxetine hydrochloride - Generic Drug Details

What are the generic sources for duloxetine hydrochloride and what is the scope of freedom to operate?

Duloxetine hydrochloride is the generic ingredient in three branded drugs marketed by Lilly, Sun Pharm, Actavis Elizabeth, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Apotex, Aurobindo Pharma Ltd, Breckenridge, Cspc Ouyi, Graviti Pharms, Hetero Labs Ltd Iii, Inventia, Lupin Ltd, Macleods Pharms Ltd, Ph Health, Prinston Inc, Qingdao Baheal Pharm, Sunshine, Teva Pharms Usa, Torrent, Yaopharma Co Ltd, Zydus Hlthcare, and Zydus Pharms, and is included in twenty-five NDAs. There are five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Duloxetine hydrochloride has one patent family member in one country.

There are forty drug master file entries for duloxetine hydrochloride. Forty-five suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for duloxetine hydrochloride

International Patents:	1
US Patents:	5
Tradenames:	3
Applicants:	24
NDAs:	25
Drug Master File Entries:	40
Finished Product Suppliers / Packagers:	45
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	380
Patent Applications:	2,770
What excipients (inactive ingredients) are in duloxetine hydrochloride?	duloxetine hydrochloride excipients list
DailyMed Link:	duloxetine hydrochloride at DailyMed

Recent Clinical Trials for duloxetine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eurofarma Laboratorios S.A.	PHASE3
Hospital de Clinicas de Porto Alegre	NA
Qilu Hospital of Shandong University	NA

See all duloxetine hydrochloride clinical trials

Generic filers with tentative approvals for DULOXETINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 60MG BASE	CAPSULE, DELAYED RELEASE; ORAL
		EQ 30MG BASE	CAPSULE, DELAYED RELEASE; ORAL
		EQ 20MG BASE	CAPSULE, DELAYED RELEASE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for duloxetine hydrochloride

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for duloxetine hydrochloride

Analgesics

Antidepressive Agents

Dopamine Agents

Serotonin and Noradrenaline Reuptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for duloxetine hydrochloride

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for DULOXETINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CYMBALTA	Delayed-release Capsules	duloxetine hydrochloride	40 mg	021427	1	2012-05-10
CYMBALTA	Delayed-release Capsules	duloxetine hydrochloride	20 mg, 30 mg and 60 mg	021427	16	2008-08-04

US Patents and Regulatory Information for duloxetine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Torrent	DULOXETINE HYDROCHLORIDE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	090774-002	Dec 11, 2013		DISCN	No	No
Torrent	DULOXETINE HYDROCHLORIDE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	090774-001	Dec 11, 2013		DISCN	No	No
Teva Pharms Usa	DULOXETINE HYDROCHLORIDE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	090783-003	Dec 11, 2013		DISCN	No	No
Sun Pharm	DRIZALMA SPRINKLE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	212516-002	Jul 19, 2019		RX	Yes	No	9,839,626		Y

Expired US Patents for duloxetine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-002	Aug 3, 2004	5,508,276*PED
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-001	Aug 3, 2004	5,023,269*PED
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-004	Aug 3, 2004	5,508,276*PED
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-001	Aug 3, 2004	5,508,276*PED

International Patents for duloxetine hydrochloride

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3335697	ÉCLATS DE DULOXÉTINE (DULOXETINE SPRINKLES)
European Patent Office	3335697	ÉCLATS DE DULOXÉTINE (DULOXETINE SPRINKLES)
European Patent Office	3335697

Supplementary Protection Certificates for duloxetine hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0273658	SPC/GB05/003	United Kingdom		PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811
0273658	2005C/001	Belgium		PRODUCT NAME: CHLORHYDRATE DE DULOXETINE; REGISTRATION NO/DATE: EU/1/04/280/001 20040811
0273658	C300171	Netherlands		PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811

Market Dynamics and Financial Trajectory for Duloxetine Hydrochloride

Last updated: January 6, 2026

Executive Summary

Duloxetine Hydrochloride, a serotonin-norepinephrine reuptake inhibitor (SNRI), is a prominent pharmaceutical agent primarily prescribed for Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), diabetic peripheral neuropathy, and fibromyalgia. Since its initial approval by the U.S. Food and Drug Administration (FDA) in 2004 under the brand name Cymbalta, the drug has experienced notable market shifts influenced by patent expirations, emerging therapeutic rivals, and evolving healthcare policies.

This comprehensive analysis examines duloxetine’s market size, competitive landscape, revenue trends, key drivers and barriers, regulatory influences, and future financial projections. Market data from global regions, especially North America and Europe, are detailed, along with comparisons to similar pharmacological classes. The strategic implications for stakeholders—including pharmaceutical companies, investors, and healthcare providers—are thoroughly discussed.

---

Summary of Market Landscape

Aspect	Insight
Market Size (2022)	Estimated global sales: $1.2 billion (IQVIA)
Major Markets	North America (55%), Europe (25%), Asia-Pacific (15%), Others (5%)
Patent Status	Patent expired in key markets (e.g., US: 2017) leading to generic entry
Key Competitors	Venlafaxine, desvenlafaxine, serotonin modulators
Growth Rate (2018-2022)	Compound Annual Growth Rate (CAGR): 4.5%

Source: IQVIA, 2022; EvaluatePharma 2022

---

What Are the Key Market Drivers for Duloxetine?

1. High Prevalence of the Target Disorders

Major depressive disorder affects approximately 280 million individuals globally (WHO, 2019), with a substantial subset prescribed duloxetine. The global prevalence of GAD is around 3.6%, reinforcing ongoing demand.

2. FDA Approvals for Multiple Indications

Duloxetine’s approval for fibromyalgia and diabetic peripheral neuropathy widened its therapeutic utility, increasing its market penetration.

3. Shifts Toward Oral, Non-Invasive Therapies

Physicians prefer oral medications with proven efficacy and tolerability, bolstering duloxetine’s prescription rates.

4. Generic Entry and Price Competition

Post patent expiry, generics have significantly lowered market prices, broadening accessibility but exerting downward pressure on revenues.

---

What Are the Main Market Barriers?

1. Generic Competition and Pricing Pressures

Generics entered the US market post-2017, leading to an approximate 60-70% drop in brand drug revenue within three years, according to IMS Health data.

2. Safety and Tolerability Concerns

Adverse events like nausea, dry mouth, and serotonin syndrome have limited broader use, especially among populations sensitive to side effects.

3. Market Saturation and Competitive Drugs

Other SNRI and SSRI drugs, such as venlafaxine and escitalopram, compete on efficacy, tolerability, and cost.

4. Regulatory and Reimbursement Challenges

Reimbursement policies increasingly favor newer, potentially more effective agents, impacting multiple indications.

---

How Has Duloxetine’s Revenue Trajectory Evolved?

Year	Global Sales (Mil$)	Notes
2018	1,450	Peak pre-generic era; stable growth
2019	1,224	Post-patent expiration
2020	1,105	Impact of COVID-19, supply chain issues
2021	950	Increased competition, pricing
2022	1,200 (estimated)	Market stabilization, generic sales accounted

Note: The 2022 estimate suggests some market recovery, potentially driven by emerging indications and regional growth.

---

Regional Market Dynamics

North America

• Dominant due to early approval, high disease burden, and established prescribing protocols.
• Patent expiration precipitated a revenue decline but enabled generic proliferation (~60% of market in 2022).
• Industry forecasts suggest a gradual stabilizing growth driven by expanded indications.

Europe

• Market mature; high adoption for depression and neuropathy.
• Reimbursement policies vary widely among countries—affecting sales.

Asia-Pacific

• Rapidly growing markets with increasing healthcare access.
• Local generics and biosimilars emerging; approximate 15% CAGR expected over five years.

Other Regions

• Less significant but rising due to increasing awareness and diagnosis rates.

---

Competitive Landscape and Product Comparisons

Drug	Class	Approved Indications	Patent Status	Key Market Share (2022)	Price Range (USD) per dose
Duloxetine	SNRI	Depression, GAD, Neuropathy, Fibromyalgia	Patented (expired in US)	25%	1.50–3.00
Venlafaxine	SNRI	Depression, GAD	Patented	20%	1.20–2.50
Escitalopram	SSRI	Depression, GAD	Patented	15%	0.90–2.00
Pregabalin	GABA Analog	Neuropathic pain, fibromyalgia	Patented	10%	2.00–4.00
Others	Various	Indications vary	-	30% combined	variable

Note: Market shares based on regional sales data; figures approximate.

---

Regulatory Policies Influencing Market Trajectory

Policy / Regulation	Impact on Duloxetine Market	Key Dates / Authorities
Patent Expiration	Surge in generic formulations; price drops	US: 2017; EU: 2018
Healthcare Reimbursement Policies	Favor generic over brand	US: Medicare Part D; EU nations adjust coverage
FDA & EMA Indications Expansion	Wider use, increased sales	FDA approvals for additional formulations or indications (e.g., generic versions in 2019)
COVID-19 Pandemic	Disruption of supply chain, deferred prescriptions	2020–2021

---

Forecasts and Future Financial Trajectory

Projections indicate a cautious recovery in duloxetine sales, driven by:

• Emerging Indications: Off-label uses and expanding approved indications (e.g., urinary incontinence in some regions).
• Regional Growth: Especially in Asia-Pacific, where healthcare infrastructure investments are rising.
• Biosimilar & Generic Competition: Continued price erosion expected, but some stabilized revenues due to regional market differences.
• Pharmacogenomics & Personalized Medicine: Potential for niche markets and specialized formulations.

Year	Projected Global Sales (Mil$)	CAGR	Remarks
2023	1,250	4.2%	Slow rebound post-patent expiry
2024	1,300	4.0%	Growing acceptance in Asia-Pacific
2025	1,350	3.8%	Emergence of biosimilars impacting pricing

---

Implications for Stakeholders

• Pharmaceutical Companies: Need for differentiation through extended indications, improved formulations, or combination therapies.
• Investors: Cautious optimism with an emphasis on regional growth and biosimilar competition.
• Healthcare Providers: Balancing efficacy, tolerability, and costs when prescribing.
• Regulators: Ensuring that safety profiles align with expanding indications.

---

Key Takeaways

• Duloxetine Hydrochloride remains a significant player in the neuropsychopharmacology market, with a valuation of approximately $1.2 billion globally in 2022.
• Patent expiration has substantially reduced revenues but opened opportunities in emerging markets and indications.
• Market dynamics are heavily influenced by drug pricing, generics, and regulatory policies, with regional disparities.
• Competitive pressures from other SNRI and SSRI drugs necessitate innovation and strategic marketing.
• Future growth depends on expanding indications, regional market development, and managing biosimilar entry.

---

FAQs

1. How has patent expiry affected duloxetine's market share?
Patent expiry in major markets like the US (2017) led to a significant decline (~60-70%) in brand revenue due to generic entry. However, it facilitated broader access and stimulated growth in emerging markets.

2. What are the main alternative therapies to duloxetine for depression?
SSRIs such as escitalopram and sertraline, as well as other SNRI drugs like venlafaxine, constitute primary alternatives, often chosen based on side effect profiles, cost, and patient-specific factors.

3. Are there new formulations or indications being developed for duloxetine?
Yes, ongoing research explores additional indications like urinary incontinence and osteoarthritis-related pain. Extended-release formulations and combination therapies are also under development.

4. How do regional policies influence duloxetine's market potential globally?
Regions with favorable reimbursement policies and healthcare infrastructure, such as Asia-Pacific and Latin America, show higher growth potential, whereas strict regulations in certain European countries may limit rapid expansion.

5. What is the outlook for biosimilars and generics impacting duloxetine?
Biosimilars and generics are expected to continue exerting price pressure, but differentiated formulations or niche indications may provide alternative revenue streams for branded manufacturers.

---

References

[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] EvaluatePharma. (2022). World Preview 2022: Outlook to 2027.
[3] World Health Organization. (2019). Depression and Other Common Mental Disorders.
[4] FDA. (2004). Approval of Cymbalta (Duloxetine Hydrochloride).
[5] Health Policy Reports. (2022). Global Drug Patent Expiration Trends.